NEW YORK and LONDON, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today the addition of biopharmaceutical industry veteran Allan Shaw to the Company's Board of Directors. Mr.

NEW YORK and LONDON, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.

NEW YORK and LONDON, June 17, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic

Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today that the annual general meeting of its shareholders will be held on Thursday, June 19, 2014 at 10:00 a.m. (Local Time, BST in UK), at 53 Davies Street, Mayfair, London W1K 5JH, United

NEW YORK and LONDON, April 7, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology Scientific Advisory Board (SAB). The SAB is comprised of: Jonathan Wilkin, MD, founding director

Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8th, at 3:40 p.m.

NEW YORK and LONDON, March 24, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, today announced its financial results and provided a review of the twelve month period ended December 31, 2013.

Celsus completes Type B pre-IND meeting with FDA for MRX-6 cream in atopic dermatitis MRX-6 to advance into Phase II trials in US upon filing of IND expected in 4Q14 NEW YORK and LONDON, March 11, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth,

NEW YORK and LONDON, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 2014 BIO CEO & Investor Conference on Monday,

American Depository Shares Listed on the NASDAQ Capital Market Under the Trading Symbol "CLTX" NEW YORK and LONDON, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq: CLTX ), an emerging growth, development-stage biotech company, announced today the closing of its previously